Investor Octagon Capital Advisors LP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Octagon Capital Advisors LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-08-12 13G/A UNCY / Unicycive Therapeutics, Inc. 1,000,000
2025-02-05 13G GOSS / Gossamer Bio, Inc. 19,576,054
2025-02-05 13G TSHA / Taysha Gene Therapies, Inc. 10,450,000
2025-02-05 13G/A DNTH / Dianthus Therapeutics, Inc. 1,746,667 2,110,167
2024-10-28 13G/A OKUR / OnKure Therapeutics, Inc. 225,000
2024-10-11 13G ALVR / AlloVir, Inc. 11,202,000
2024-10-11 13G DNTH / Dianthus Therapeutics, Inc. 1,746,667
2024-10-11 13G CRBP / Corbus Pharmaceuticals Holdings, Inc. 1,115,000
2024-10-11 13G UNCY / Unicycive Therapeutics, Inc. 8,559,000
2024-10-11 13G AVBP / ArriVent BioPharma, Inc. 1,976,387
2024-10-11 13G RGLS / Regulus Therapeutics Inc. 4,263,701
2024-08-28 13G/A ANTX / AN2 Therapeutics, Inc. 3,009,927 0
2024-07-03 13G ANTX / AN2 Therapeutics, Inc. 3,009,927
2024-02-06 13G/A XLO / Xilio Therapeutics, Inc. 1,785,000 0
2024-02-05 13G/A XLO / Xilio Therapeutics, Inc. 2,425,000 1,785,000
2024-02-05 13G RPHM / Reneo Pharmaceuticals, Inc. 2,250,000
2023-01-25 13G XLO / Xilio Therapeutics, Inc. 2,425,000